As a comparator, we analyzed 18 cases of AML with core-binding factor (CBF) translocations, which have defined structural alterations – inv(16) with CBFB::MYH11 or t(8;21) with RUNX1::RUNX1T1 fusions – and lack TP53 mutations or complex cytogenetics (Table 1). This evidence concerns the gene TP53 and acute myeloid leukemia.